Document Detail


Cryofiltration apheresis in the United States.
MedLine Citation:
PMID:  10227775     Owner:  NLM     Status:  MEDLINE    
Abstract/OtherAbstract:
There are approximately 2,000 cases of cryoglobulinemia reported each year in the United States. The number of cases has been and is expected to continue growing exponentially since the advent of its association with the hepatitis C virus (HCV). Cryofiltration apheresis is a specific therapy for the treatment of cryoprotein induced diseases that selectively removes cryoprecipitates. We are currently the only center in the United States performing cryofiltration apheresis. We report on 32 patients treated with over 920 cryofiltration apheresis procedures over the last 6 years under the Investigational Device Exemption of the Food and Drug Administration Office of Orphan Devices. Twenty-seven patients were treated for cryoglobulinemia. Twelve of these patients received maintenance cryofiltration apheresis at some point, and 5 patients died. Five of the 32 patients were treated for cold IgM agglutinin disease. Only 2 of these patients, having plasma positive for cryoprotein and a high titer antibody, responded to therapy. None of these patients received maintenance therapy. No complement activation was observed using the cryofilter by measuring C3a and C5a. Although cryoproteins were effectively removed from the plasma, the other vital proteins such as immunoglobulins, albumin, and fibrinogen were preserved. Therefore cryofiltration apheresis is safe and effective in treating cryoprotein induced diseases. We would like to see widespread use of this cryofilter so that all patients with cryoprotein induced diseases such as cryoglobulinemia may benefit from this procedure.
Authors:
G A Siami; F S Siami
Related Documents :
20671975 - Targeted immunotherapy with rituximab leads to a transient alteration of the igg autoan...
2330115 - Lower motor neuron disease in a patient with autoantibodies against gal(beta 1-3)galnac...
6401765 - Hla-dr antigens in mexican patients with guillain-barré syndrome.
12153365 - Autoantibodies in lepromatous leprosy.
9804365 - Plasma and csf benzodiazepine receptor ligand concentrations in cirrhotic patients with...
7316755 - Prognosis of patients with transient ischemic attacks and normal angiograms.
Publication Detail:
Type:  Journal Article; Research Support, U.S. Gov't, P.H.S.    
Journal Detail:
Title:  Therapeutic apheresis : official journal of the International Society for Apheresis and the Japanese Society for Apheresis     Volume:  2     ISSN:  1091-6660     ISO Abbreviation:  Ther Apher     Publication Date:  1998 Aug 
Date Detail:
Created Date:  1999-05-19     Completed Date:  1999-05-19     Revised Date:  2009-11-19    
Medline Journal Info:
Nlm Unique ID:  9706703     Medline TA:  Ther Apher     Country:  UNITED STATES    
Other Details:
Languages:  eng     Pagination:  228-35     Citation Subset:  IM    
Affiliation:
Department of Medicine, Division of Nephrology, Vanderbilt University Medical Center, and Department of Veterans Affairs Medical Center, Nashville, Tennessee 37212-2637, USA.
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Descriptor/Qualifier:
Adult
Aged
Anemia, Hemolytic, Autoimmune / therapy
Chemical Precipitation
Complement Activation
Complement C3a / analysis
Complement C5a / analysis
Cryoglobulinemia / therapy*
Cryotherapy
Female
Fibrinogen / analysis
Hepatitis C / complications
Humans
Immunoglobulin M / blood
Immunoglobulins / blood
Male
Middle Aged
Plasmapheresis / instrumentation,  methods*
Safety
Serum Albumin / analysis
Survival Rate
United States
United States Food and Drug Administration
Chemical
Reg. No./Substance:
0/Immunoglobulin M; 0/Immunoglobulins; 0/Serum Albumin; 80295-42-7/Complement C3a; 80295-54-1/Complement C5a; 9001-32-5/Fibrinogen

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine


Previous Document:  Double filtration plasmapheresis maintains normal adhesion molecule levels.
Next Document:  Cryosupernatant plasma exchange in the treatment of antiphospholipid antibody syndrome with lupus ne...